Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen, Jeffrey A;Barkhof, Frederik;Comi, Giancarlo;Hartung, Hans-Peter;Sindic, Christian;et.al.
(2010) New England Journal of Medicine — Vol. 362, n° 5, p. 402-415 (2010)

Files

Oralfingolimodorintramuscular.pdf
  • Open Access
  • Adobe PDF
  • 359.86 KB
Download

Details

Authors
  • Cohen, Jeffrey A
    Author
  • Barkhof, Frederik
    Author
  • Comi, Giancarlo
    Author
  • Hartung, Hans-Peter
    Author
  • Sindic, ChristianUCLouvain
    Author
Show more
Abstract
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a. Longer studies are needed to assess the safety and efficacy of treatment beyond 1 year. (ClinicalTrials.gov number, NCT00340834.)
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., & Sindic, C. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine, 362(5), 402-415. https://doi.org/10.1056/NEJMoa0907839 (Original work published 2010)